A Jeff Bezos-backed startup just inked a deal with $84 billion biotech Gilead to make drugs for a troubling and increasingly common disease (GILD)
|04/16/2019||Posted by BusinessMediaguide.Com under General World News||
- Pharmaceutical giant Gilead is teaming up with Silicon Valley startup Insitro to develop better drugs for a quietly emerging disease called NASH.
- Short for non-alcoholic steatohepatitis, NASH can lead to liver failure and is estimated to affect some 16 million Americans.
- Insitro is led by the former chief computing officer of Google life-extension spinoff Calico. It has backing from top-notch tech investors like Jeff Bezos and life science firms like Verily.
- The three-year deal could be worth as much as $250 million for Insitro.
- Visit BusinessInsider.com for more stories.
The world’s leading drug companies are racing to read more >>>